Dibucaine Mitigates Spreading Depolarization in Human Neocortical Slices and Prevents Acute Dendritic Injury in the Ischemic Rodent Neocortex by Risher, W. Christopher et al.
Dibucaine Mitigates Spreading Depolarization in Human
Neocortical Slices and Prevents Acute Dendritic Injury in
the Ischemic Rodent Neocortex
W. Christopher Risher
1,4¤a, Mark R. Lee
2¤b, Ioulia V. Fomitcheva
2, David C. Hess
3,4, Sergei A. Kirov
2,4*
1Graduate Program in Neuroscience, Georgia Health Sciences University, Augusta, Georgia, United States of America, 2Department of Neurosurgery, Georgia Health
Sciences University, Augusta, Georgia, United States of America, 3Department of Neurology, Georgia Health Sciences University, Augusta, Georgia, United States of
America, 4Brain and Behavior Discovery Institute, Georgia Health Sciences University, Augusta, Georgia, United States of America
Abstract
Background: Spreading depolarizations that occur in patients with malignant stroke, subarachnoid/intracranial
hemorrhage, and traumatic brain injury are known to facilitate neuronal damage in metabolically compromised brain
tissue. The dramatic failure of brain ion homeostasis caused by propagating spreading depolarizations results in neuronal
and astroglial swelling. In essence, swelling is the initial response and a sign of the acute neuronal injury that follows if
energy deprivation is maintained. Choosing spreading depolarizations as a target for therapeutic intervention, we have
used human brain slices and in vivo real-time two-photon laser scanning microscopy in the mouse neocortex to study
potentially useful therapeutics against spreading depolarization-induced injury.
Methodology/Principal Findings: We have shown that anoxic or terminal depolarization, a spreading depolarization wave
ignited in the ischemic core where neurons cannot repolarize, can be evoked in human slices from pediatric brains during
simulated ischemia induced by oxygen/glucose deprivation or by exposure to ouabain. Changes in light transmittance (LT)
tracked terminal depolarization in time and space. Though spreading depolarizations are notoriously difficult to block,
terminal depolarization onset was delayed by dibucaine, a local amide anesthetic and sodium channel blocker. Remarkably,
the occurrence of ouabain-induced terminal depolarization was delayed at a concentration of 1 mM that preserves synaptic
function. Moreover, in vivo two-photon imaging in the penumbra revealed that, though spreading depolarizations did still
occur, spreading depolarization-induced dendritic injury was inhibited by dibucaine administered intravenously at 2.5 mg/
kg in a mouse stroke model.
Conclusions/Significance: Dibucaine mitigated the effects of spreading depolarization at a concentration that could be
well-tolerated therapeutically. Hence, dibucaine is a promising candidate to protect the brain from ischemic injury with an
approach that does not rely on the complete abolishment of spreading depolarizations.
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Introduction
Within minutes of focal stroke onset, a spreading depolarization
originates from an area of severely decreased blood flow known as
the ischemic core [1–4]. In the core, where neurons do not
repolarize, this prolonged spreading depolarization is called the
anoxic or terminal depolarization [4]. It propagates into the
ischemic penumbra along a decreasing gradient of metabolic stress
and into normoxic tissue where it becomes short-lasting [5–10].
Recurring spontaneous spreading depolarizations arising at the
perimeter of the core propagate throughout the penumbra for
hours to days in animal models and patients [11–17]. The pro-
longed duration of recurring spreading depolarizations further
elevates metabolic stress in the penumbra due to the mismatch
between energy supply and needs for recovery. Eventually pe-
numbral neurons and astrocytes remain depolarized and over-
loaded with Ca
2+, recruiting the tissue into infarct [11,16,18–20].
It has been proposed that a useful anti-stroke drug should abrogate
spreading depolarizations without depressing normal synaptic
function [4,21]. We have recently shown that one such candidate
is dibucaine, an FDA-approved local amide anesthetic and sodium
channel blocker that potently inhibits terminal depolarization in
rat brain slices while preserving synaptic function [22]. However,
nearly all clinical trials of drugs that were effective in animal
models of stroke/ischemia have failed, with the limited complexity
of animal models compared to human stroke as well as fun-
damental differences between the brains of animals and humans
assumed as contributing factors [23]. It is recognized by stroke
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forecast translational success before clinical trials [24]. Towards
this end, we used light transmittance (LT) imaging to confirm that
dibucaine diminishes the impact of terminal depolarization on live
human neocortical slices prepared from pediatric brain tissue
mostly resected for the treatment of intractable epilepsy as well as
for neoplasm removal. We supplemented human slice experiments
with a sophisticated in vivo approach using real-time 2-photon laser
scanning microscopy (2PLSM) to show that spontaneous spreading
depolarization-elicited dendritic damage is greatly reduced fol-
lowing photothrombosis-induced focal ischemia in dibucaine-
treated mice. This success of dibucaine in reducing the negative
effects of spreading depolarization makes it a strong candidate for
further investigation to prevent spreading depolarization-induced
neuronal damage in the acutely injured brain.
Materials and Methods
Ethics Statement
All protocols involving human tissue were approved by the
Institutional Review Board at Georgia Health Sciences Univer-
sity. Written parents’ informed consent documents and written
children’s assent documents were obtained prior to each study. All
animal procedures were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol for this study was specifically approved by the Animal
Care and Use Committee at Georgia Health Sciences University
(Permit Number 08-05-051). All surgery was performed under
urethane anesthesia and all efforts were made to minimize animal
discomfort and reduce the number of animals used.
Human Slice Preparation and Solutions
Human neocortical slices were made as previously described
[25] from tissue resected from a total of 23 pediatric patients
(average age,9 y.o.) of both genders undergoing surgery for
pharmacoresistant epilepsy (20 patients from whom tissue was
used in the described experiments; these patients are listed in the
Patient Table S1). Written parents’ informed consent documents
and written children’s assent documents were obtained prior to
each study. All protocols were approved by the Institutional
Review Board at Georgia Health Sciences University. Coronal
slices (400 mm) were cut using a vibrating-blade microtome
(VT1000S, Leica Instruments) with ice-cold oxygenated sucrose-
based artificial cerebrospinal fluid (Sucrose-ACSF) containing (in
mM) 100 sucrose, 60 NaCl, 2.5 KCl, 26 NaHCO3, 1.25
NaH2PO4, 1 CaCl2, 5 MgCl2, 10 glucose, pH 7.4, 290 mOsm/
kg H2O. Slices were transferred into an incubation chamber and
maintained at room temperature for at least 1 hour in standard
oxygenated ACSF containing (in mM) 125 NaCl, 2.5 KCl, 26
NaHCO3, 1.25 NaH2PO4, 2 CaCl2, 1 MgCl2, 10 glucose, pH 7.4,
290 mOsm/kg H2O. Some slices were transferred into a separate
incubation chamber and pretreated for 1 hour at room temper-
ature with ACSF containing 1 or 10 mM dibucaine hydrochloride
(cinchocaine) [2-butoxy-N-(2-diethylaminoethyl) quinoline-4-car-
boxamide hydrochloride] or 0.1, 1, 5 or 100 mM minocycline. For
imaging, a slice was transferred into a submersion-type imaging/
recording chamber (RC-29, Warner Instruments) at 34uC and
held down by an anchor (SHD-27LP/2, Warner). For oxygen/
glucose deprivation (OGD, 20 min duration), ACSF was bubbled
with 95%N2–5%CO2 and glucose lowered to 1 mM. NaCl was
added to ACSF to osmotically balance the removed glucose.
100 mM ouabain was added to ACSF for chemical ischemia
(15 min duration). Terminal depolarization induced by ouabain
has been shown to elicit changes in LT, electrophysiology and
drug effects indistinguishable from those seen following OGD-
induced depolarization [21,22,26]. Therefore, we use the term
‘terminal depolarization’ for both OGD-induced depolarization
and for the ouabain-induced depolarization. All chemicals were
from Sigma Chemical unless indicated otherwise.
Intrinsic Optical Imaging
Intrinsic optical signals were acquired as previously described
following standard protocols [22,27,28]. Slices were transillumi-
nated with a broadband, halogen light source (Carl Zeiss) through
a near-infrared pass filter. LT was collected with 2.56/0.075NA
air objective with dipping cone attachment [29] using the mo-
torized upright Axioscope-2FS microscope (Zeiss) with IR-1000
CCD camera (Dage-MTI). Image frames were acquired at 30 Hz,
digitized and averaged using a frame grabber controlled by Scion
Imaging Software. Each image was generated by averaging 128
frames. The control image (Tcont) was subtracted from each
subsequent experimental image (Texp), resulting in an image series
that revealed changes in LT over time [21,22,27,28]. The LT
change was expressed as the digital intensity of subtracted images
(Texp-Tcont) and displayed using a pseudocolor intensity scale.
‘Zones of interest’ were created in the images to quantify the data,
with at least one zone positioned near the origin of the terminal
depolarization front to record onset time. The difference (Texp-
Tcont) was normalized by dividing by Tcont which varies across the
slice depending on the zone sampled. To accommodate for
potential sample variables, we always compared control and drug-
treated slices within tissue from the same patient.
Transgenic Mice
All animal procedures follow NIH guidelines and underwent
yearly review by the Animal Care and Use Committee at Georgia
Health Sciences University (Permit Number 08-05-051). All efforts
were made to minimize animal discomfort and reduce the number
of animals used. Founders of the B6.Cg-Tg(Thy1-EGFP)MJrs/J
colony [GFP-M] were kindly provided by Dr. J. Sanes (Harvard
University, Boston, MA). 12 GFP-M and 12 wild-type C57BL/6J
male and female mice (average age,4 months) were used in this
study. Control data for in vivo experiments were taken from 24
GFP-M male and female mice (average age,4 months) which
were tested without drug treatment in a previous study [15]
concurrently with the dibucaine-treated mice.
Mouse Slice Preparation and Electrophysiology
Acute murine slices (400 mm) were made from C57BL/6J mice
according to standard protocols [30,31]. Field excitatory postsyn-
aptic potentials (fEPSPs) were recorded in the middle of stratum
radiatum of hippocampal area CA1. Signals were recorded with
MultiClamp 200B amplifier, filtered at 2 kHz, digitized at 10 kHz
with Digidata 1322A interface board and analyzed with pClamp 9
software (Molecular Devices). Stimuli (100 ms duration) ranging
from 10–200 mA were applied via small concentric bipolar
electrode (25 mm pole separation; FHC). The slope function
(mV/ms) of the fEPSP was measured from the steepest 400 ms
segment of the negative field potential.
Preparation of Mice for In Vivo Imaging
Craniotomy for the optical window followed standard protocol
[15]. Mice were anesthetized with an intraperitoneal injection of
urethane (1.5 mg/g body weight) with heart rate monitored (450–
650 beats/min) using MouseOxH pulse oximeter (STARR Life
Sciences). Depth of anesthesia was assessed by toe pinch and heart
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if necessary. Oxygen saturation level remained .90% for duration
of experiments, indicating that mice were respiring properly under
our imaging conditions. Hydration was maintained by intraper-
itoneal injection of 100 ml 0.9% NaCl with 20 mM glucose at
1 hour intervals. A 0.1 ml bolus of 5% (w/v) Texas Red Dextran
(70 kDA) (Invitrogen) in 0.9% NaCl was injected into the tail vein
for blood flow visualization. An optical chamber was constructed
by covering the intact dura with a thin layer of 1.5% agarose
prepared in a cortex buffer containing (in mM) 135 NaCl, 5.4
KCl, 1 MgCl2, 1.8 CaCl2, and 5 HEPES, pH 7.3. The optical
chamber was left open to facilitate access with a glass micro-
electrode inserted through dura and used to record the cortical
slow direct current (DC) potential with MultiClamp 200B ampli-
fier at the site of imaged dendrites within layer I of somatosensory
cortex. The Ag/AgCl pellet reference electrode (A-M Systems) was
installed under the skin above the nasal bone. In a subset of mice,
we assessed whether injection of a bolus of dibucaine hydrochlo-
ride into the tail vein (0.1 mL, 2.5 mg/kg, diluted in 0.9% NaCl)
affects blood gas parameters. Mice were anesthetized with
urethane (1.5 mg/g body weight) and one hundred microliters
of blood were collected from a common carotid artery ,1 h after
dibucaine treatment and immediately quantified with a CG8+
blood gas cartridge and iStat1 blood gas analyzer (Abbott).
Corresponding blood parameters were measured at ,1 h in age-
and sex-matched control mice that were anesthetized with
urethane (1.5 mg/g body weight). Blood oxygen level and the
acid–base balance were not statistically different in dibucaine-
treated and control mice (t-test).
2PLSM
2PLSM images were collected with an IR-optimized 406/
0.8NA water immersion objective using the LSM 510 NLO
META multiphoton system (Zeiss) mounted on the motorized
upright Axioscope-2FS microscope. The scan module was directly
coupled with the Spectra-Physics Ti:sapphire broadband mode-
locked laser (Mai-Tai) tuned to 910 nm for 2-photon excitation.
Three-dimensional time-lapse images were taken at 1 mm
increments using 36 optical zoom, yielding a nominal spatial
resolution of 6.86 pixels/mm (12 bits/pixel, 0.91 ms pixel time)
across a 75675 mm imaging field. Image Examiner (Zeiss) was
used together with NIH ImageJ for image analysis. Dendritic
beading was identified as the appearance of rounded regions
extending beyond the diameter of the parent dendrite separated
by ‘‘interbead’’ segments. Dendritic recovery was defined as the
disappearance of rounded ‘‘beaded’’ regions.
Photothrombotic Stroke Model
Photothrombotic occlusion was implemented as described
recently [15]. A bolus of Rose Bengal was injected through the
tail vein (0.03 mg/g, diluted to 10 mg/ml in 0.9% NaCl). With
LSM 510 software, the perimeter (100 mm wide) of a square-
shaped region of interest (ROI, 127061270 mm) was irradiated
with the 514 nm laser line through a 106/0.3NA water immer-
sion objective. The central square (107061070 mm) was not
illuminated by the laser. Photothrombosis was stopped immedi-
ately upon occurrence of initial induced spreading depolarization
recorded in the vicinity of imaged dendrites approximately in the
center of the ROI. A bolus of dibucaine hydrochloride was
injected into the tail vein (0.1 mL, 2.5 mg/kg, diluted in 0.9%
NaCl) immediately after the onset of photothrombotically-induced
spreading depolarization (or at 30 min after the onset of induced
spreading depolarization in a subset of experiments).
Statistics
Statistica (StatSoft) was used to evaluate significant differences
between conditions with two-way ANOVA. Two-tailed unpaired
Student’s t test, two-way repeated measures (RM) ANOVA, one-
way ANOVA, one-way RM ANOVA and Chi-Square test were
used when applicable. The significance criterion was p,0.05.
Data are presented as mean6s.e.m.
Results
To test candidate neuroprotectants’ ability to mitigate terminal
depolarization in human tissue, we first confirmed that propagat-
ing terminal depolarization can be reliably generated in human
neocortical slices from pediatric patients. A near-complete break-
down of the ion concentration gradients associated with pro-
pagating terminal depolarization causes dramatic neuronal and
astroglial swelling, dendritic beading and spine loss within seconds,
leading to acute cell death [7,27,31–33]. Terminal depolarization-
induced swelling of neurons and glia results in increased tissue
transparency, appearing as an elevated LT wave [22,27,28,34,35].
Terminal depolarization rapidly induces dendritic beading which
scatters light, lowering LT in swollen tissue [22,27,36]. By imaging
changes in LT we verified that terminal depolarization can be
evoked in human slices exposed to OGD (Fig. 1A) or 100 mM
ouabain (Fig. 2A, top row). A wave of elevated LT, signifying
terminal depolarization, was elicited between 6–17 min during
OGD (10.9160.56 min; n=27 slices) and between 5–10 min
during exposure to ouabain (6.8360.26 min; n=22 slices). Ter-
minal depolarization spread throughout gray matter at 2.316
0.42 mm/min. Terminal depolarization onset and speed of
propagation were independent of patients’ age and gender, as
well as the cortical region of the resected tissue. Thus, neocortical
slices from human pediatric brain tissue were viable and supported
terminal depolarization.
We next investigated whether dibucaine can inhibit terminal
depolarization in human slices. In control slices, terminal depo-
larization was induced by superfusion with ACSF containing the
Na
+/K
+-ATPase inhibitor ouabain (Fig. 2A, top row; Video S1).
Slices from the same patient were pretreated for 1 hour with either
1o r1 0mM dibucaine-containing ACSF, then ouabain was co-
superfused with dibucaine-containing ACSF to induce terminal
depolarization (Fig. 2A, middle and bottom rows respectively;
Videos S2, S3). These concentrations were tested in mouse hip-
pocampal slices for effects on evoked synaptic activity (Fig. 1B–D).
Similar to our recent study in rat neocortical slices, 1 mM dibucaine
largely preserved synaptic function [22]. The images in Fig. 2A
show a noticeably subdued response to terminal depolarization in
dibucaine-pretreated human slices. Quantification shows increased
latency to terminal depolarization onset (Fig. 2B) induced by
ouabain in 1 and 10 mM dibucaine-pretreated slices. Due to the
limited availability of human tissue only 10 mM dibucaine was
tested against OGD-induced terminal depolarization. At this
concentration dibucaine was effective in significantly delaying the
onset of OGD-induced terminal depolarization (Fig. 2B). Decreased
peak LT during ouabain-induced terminal depolarization was
significant only in slices treated with 1 mM dibucaine (Fig. 2C). By
comparison, pretreatment for 1 hour with the neuroprotective
antibiotic minocycline (0.1,1, 5 and 100 mM) [33] had no effect on
the cellular response to terminal depolarization. In addition,
ANOVA has shown that tissue response to dibucaine treatment
was independent of gender and age of these pediatric patients (data
not shown). We confirm that human brain slices represent a viable
approach for screening candidate therapeutic drugs that target
spreading depolarization, and that dibucaine is one such drug.
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depolarization in human brain slices and temper its effects in
rodent slices (Douglas et al., 2011), we then wanted to see if its
protective properties would extend to the ischemic penumbra in
vivo by preventing injury to fine synaptic circuitry caused by
recurrent waves of spontaneous depolarizations. We recently used
a photothrombotic occlusion model [37] which employs the
photosensitive dye Rose Bengal (RB) to create a focal ischemic
lesion enclosing a penumbra-like ‘‘area at risk’’ in intact mice [15].
We used 2PLSM in the center of this area at risk to show that
acute neuronal injury represented by dendritic beading was highly
correlated with the occurrence of the initial spreading depolariza-
tion induced during RB photoactivation as well as with subsequent
spontaneous spreading depolarizations (Fig. 3A). Nearly all
Figure 1. Global monitoring of terminal depolarization (TD) in human and mouse brain slices during dibucaine exposure. A, A slice is
transilluminated and transmitted light is collected by CCD camera to create the digital bright field image (left). Following OGD at 0 min, the gray
matter displays a propagating wave of elevated LT (signifying terminal depolarization), represented by pseudocoloring according to changes in pixel
values of the image (color scale: below, right). In this example, terminal depolarization is ignited within 13 minutes of OGD and spreads in all
directions (arrows). Scale bar, 500 mm. B, fEPSPs recorded from CA1 of st. radiatum in mouse hippocampal slices are not noticeably affected by 1 hour
of superfusion with ACSF containing 1 mM dibucaine. 10 mM dibucaine partially inhibited the evoked synaptic response, while 100 mM dibucaine
completely abolished synaptic activity. Each row represents traces recorded from a single slice. C, Summary of synaptic responses during dibucaine
exposure. Following 1 hour of control recording in standard ACSF, slices were superfused with ACSF containing 1 mM (left panel; n=3 slices) or
10 mM dibucaine (right panel; n=3 slices). At the end of 1 hour treatment with 1 mM dibucaine, ,82% of the control fEPSP slope was preserved;
10 mM dibucaine reduced the fEPSP slope to ,14% of control values (p,0.0001 for both; one-way ANOVA). D, Input/output graphs showing mean
fEPSP slope at various stimulus intensities before and after 1 hour treatment with either 1 mM (left) or 10 mM (right) dibucaine (n=3 slices for each
concentration; *p,0.05, **p,0.001; two-way ANOVA).
doi:10.1371/journal.pone.0022351.g001
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beading regardless of whether there was a nearby flowing blood
vessel. This beading was typically reversible in the presence of
nearby flowing blood vessels [15]. Here, dibucaine was adminis-
tered immediately after the onset of photothrombotically-induced
spreading depolarization. Though dibucaine did not inhibit the
occurrence of spontaneous spreading depolarizations (12 sponta-
neous spreading depolarizations from 8 animals, compared to 35
spontaneous spreading depolarizations in 24 control animals),
dendritic structure remained remarkably stable following recovery
from initial induced spreading depolarization (Fig. 3B). Dibucaine
significantly reduced the percentage of spontaneous spreading
depolarizations that were temporally correlated with dendritic
beading (Fig. 3C). When beading did occur during spontaneous
spreading depolarization, bead density was decreased (Fig. 3D)
though spine density was unaffected (Fig. 3E). Dibucaine’s pre-
vention of dendritic beading did not appear to be related to local
perfusion since the frequency of observations of flowing versus non-
flowing vessels near imaged dendrites did not change with recurring
spontaneous spreading depolarizations (p=0.7; Chi-Square Test).
Intriguingly, in a subset of 4 mice in which dibucaine injection was
delayed until 30 min after photothrombotically-induced initial
spreading depolarization, no beading was seen following dibucaine
administration. Additionally, dibucaine treatment did not affect the
quantitative features of spontaneous spreading depolarizations
(p.0.05, Mann–Whitney U test, data not shown), such as ampli-
tude (potential difference between start of SD and the lowest point
of the DC deflection), duration (time between the points cor-
responding to half the DC amplitude and the same potential during
recovery), maximum rate of depolarization (taken from steepest 4 s
segment of SD), and onset time (relative to time of initial induced
SD onset and time since the previous SD). Nevertheless, dibucaine-
treated mice had significantly fewer incidents of terminal dendritic
beading(i.e.beadingwithoutfurtherrecovery), occurring injust1 of
11 mice (compared to 13 of 17 control mice).
Discussion
We simulated ischemia in human neocortical slices to test the
efficacy of candidate anti-stroke drugs in mitigating the effects of
terminal depolarization. Ouabain-induced depolarization closely
resembles terminal depolarization induced by OGD, and therefore
both treatments are often used in rodent neuroprotective studies
[21,22], but rarely in human slices. Fundamental differences
Figure 2. Dibucaine pretreatment delays terminal depolarization in human neocortical slices. A, Changes in LT (DLT) are utilized to track
terminal depolarization in real time. The first image in each row shows bright field image of the slice. A control untreated slice incubated in standard
ACSF (top row) undergoes terminal depolarization within 5 minutes of superfusion with 100 mM ouabain. Pseudocolored elevated DLT indicates cell
swelling. In slices pretreated with either 1 or 10 mM dibucaine for 60 min (middle and bottom rows, respectively), ouabain-induced terminal
depolarization is delayed by 2.1 and 4.8 min respectively and has less impact in terms of cell swelling. All three slices were from the same patient (#7;
see Patient Table S1). Scale bar, 1 mm. B, Pretreatment for 1 hour with dibucaine significantly increases the latency to terminal depolarization onset
induced by 100 mM ouabain or OGD when compared to untreated control slices from the same patient. C, Peak cell swelling during terminal
depolarization in the same slices pretreated with dibucaine. The neuroprotective anti-inflammatory drug minocycline had no effect on terminal
depolarization. Numbers of slices in each condition are indicated within each bar. Values are shown as percent of control (untreated slices from the
same patient). Asterisks indicate significant differences from control (*p,0.05, **p,0.001, two-way ANOVA).
doi:10.1371/journal.pone.0022351.g002
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possible reasons why neuroprotective drugs that were effective in
rodent models have failed in clinical stroke trials [23]. Energy
failure during stroke is universal between species, but cerebral
energy metabolism, blood flow and brain size vary. The human
brain is larger and gyrated, reflecting increased size and number of
neurons [7]. Phylogenetic changes are also reported, as human
astrocytes are bigger, more complex and diverse [38]. Spreading
depolarization under normoxic conditions can be elicited in
human neocortical slices by potassium application, but the
threshold is higher than in rat slices [39]. Human and rodent
neocortical slices are different with respect to the latency of
terminal depolarization onset induced by OGD (,11 min human
vs. ,5.5 min rat slices [22]) or by ouabain (,7 min human vs.
,5 min rat slices [22]). Spreading depolarization cannot be
triggered in the brains of newborn animals [7], but human
neocortical slices obtained from even very young pediatric patents
(,2 y.o.) support terminal depolarization. We have therefore used
an in vitro assay with human slices to test whether drugs shown to
be effective in rodent models are also effective in human tissue.
Patient variables including age, gender, seizure etiology,
resected cortical region, duration of the seizure disorder, age of
onset, histopathological findings and history of medication may
systematically affect tissue response. For those reasons, we always
Figure 3. Dibucaine lessens dendritic beading induced by spontaneous spreading depolarizations (SDs) in penumbra. A, In vivo
2PLSM image sequence of dendrites (green) and a nearby flowing blood vessel (red; blood flow is indicated by stripes within vessel) from intact
mouse somatosensory cortex. The images were taken from the center of the penumbra-like ‘‘area at risk’’, surrounded by partially occluded blood
vessels [15]. The dendrites bead (asterisks) during the initial spreading depolarization induced by cortical photothrombosis. The dendrites rapidly
(,3 min) recover but become beaded again by the next spontaneous spreading depolarization even in the presence of a flowing blood vessel before
recovering once more. Scale bar, 20 mm. B, Similar sequence to that shown in A, except dibucaine (2.5 mg/kg) was injected into the tail vein
immediately after the onset of induced spreading depolarization. As in A, the dendrite rapidly recovers from beading (asterisks) induced by the initial
spreading depolarization, but unlike the dendrites shown in A, the dendrite in the dibucaine-treated animal does not bead during a spontaneous
spreading depolarization. Scale bar, 20 mm. C, Summary showing significantly decreased occurrence of dendritic beading (*p,0.05; Chi-Square Test)
when dibucaine is administered i.v. immediately following onset of the initial spreading depolarization. D, Bead density during spontaneous
spreading depolarizations is significantly decreased with dibucaine while E, spine density remains unaffected. Densities were assessed from random
30 mm segments of 3 dendrites in each imaging field as observed in maximum intensity projections of three-dimensional stacks in 5 control and 8
dibucaine treated mice. Data points (representing averages taken from individual dendrites) were only used when an image was taken near the peak
of a recorded spreading depolarization. Values are shown as percentages of bead (D) or spine (E) density immediately after induced spreading
depolarization (*p,0.05; two-way RM ANOVA).
doi:10.1371/journal.pone.0022351.g003
Neuroprotection against Spreading Depolarization
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22351compared control and drug-treated experiments within tissue from
the same patient and severely sclerotic tissue was excluded. The
lack of ‘‘normal’’ tissue is a problem inherent to studies conducted
on live human brain tissue in vitro, because obviously normal tissue
cannot be removed. Nevertheless, testing candidate neuroprotec-
tants in human brain slices was recognized in ‘‘The 2007 Feinberg
lecture: a new road map for neuroprotection’’ as one crucial new
step for developing novel therapies [24]. Epilepsy resections are
the best source of differentiated viable human brain tissue
available, and other investigators have used such tissue in similar
studies [39,40]. It is conceivable that the sensitivity of terminal
depolarization to dibucaine in slices from the epileptic cortex may
differ from normal cortex. ‘‘Non-epileptic’’ normal tissue is
sometimes available, such as in the example shown in Fig. 2A
where part of the occipital cortex was removed to access a benign
tumor deeply located in the ventricle. This example is not different
from our observations made in slices from epileptic cortex.
Terminal depolarization persistently resists pharmacological
abrogation with blockers of voltage or ligand-gated ion channels
[41], with the only successful attempts using a cocktail of gluta-
mate receptor antagonists and voltage-dependent channel blockers
[42,43]. However, Yamada and co-authors [44] used rat hip-
pocampal slices to show that 10 mM dibucaine prolonged the
latency to OGD-induced terminal depolarization, decreased the
maximal slope of this depolarization and induced partial recovery
of neuronal membrane potential after reoxygenation/normogly-
cemia. Additionally, by measuring changes in LT and field
potentials, Douglas and co-authors [22] reported that 1 mM
dibucaine remarkably inhibits terminal depolarization in rat
neocortical slices without altering synaptic function. Though
dibucaine did not abolish terminal depolarization in human
neocortical slices in our current studies, we observed that ouabain-
induced terminal depolarization onset was delayed at the 1 mM
concentration that preserved synaptic responses [22], indicating
that this concentration could be well-tolerated therapeutically with
minimal electrophysiological consequences. Terminal depolariza-
tion induced by OGD is more difficult to block than by ouabain
[21,22], perhaps because all energy requiring processes are
inhibited by OGD, not just the Na
+/K
+-ATPase as in case of
ouabain. OGD-induced terminal depolarization was delayed
by 10 mM dibucaine in our experiments. Due to the limited
availability of the human tissue, effectiveness of 1 mM dibucaine
against OGD-induced terminal depolarizations was not tested in
the current study, so future experiments (pending tissue availabil-
ity) may be required to test lower concentrations of dibucaine
against OGD-induced terminal depolarization. Furthermore,
these findings from tissue resected from pediatric patients should
ideally be compared to that from aged brains that are more at risk
for stroke. Nevertheless our current study shows that dibucaine-
like drugs could prove to be capable in protecting human brain
from spreading depolarization-induced injury. It should be noted,
though, that dibucaine is only approved for topical use by the FDA
and may not be safe via an intravenous route. Its sister drug,
lidocaine, is used to treat cardiac arrhythmias and its major side
effects (e.g. CNS depression and convulsions) indicate that it
crosses the blood brain barrier (BBB). Indeed, lidocaine was
experimentally shown to be readily available for transport into the
brain parenchyma across the BBB [45]. When lidocaine was
injected i.v. in rabbits (4 mg/kg), it resulted in seizures with the
cortical brain lidocaine level at 80620 mg/ml and CSF lidocaine
at 2165 mg/ml [46]. Dibucaine injected i.v. can also cause
seizures, as has been shown in animal models [47]. Additionally,
accidental dibucaine overdose in pediatric patients results in
seizures within minutes, indicating that it crosses the BBB [48].
Propagating terminal depolarization is difficult to spatially
monitor in slices without complicated electrode arrays. Therefore,
we used changes in LT to monitor this depolarization in time
and space. In submerged slices, terminal depolarization-induced
cellular swelling is the major source of increased LT [27,28,36].
Alternatively, direct imaging of dendritic injury and recovery with
2PLSM is a powerful approach to unambiguously monitor
structural changes. Recently we have used 2PLSM imaging of
single GFP-expressing neurons in mouse slices to demonstrate that
dibucaine pretreatment was remarkably effective in reversing
terminal depolarization-induced neuronal somata swelling and
dendritic beading, with complete protection in some experiments
[22]. Therefore, future 2PLSM experiments will be necessary to
address the neuroprotective properties of dibucaine at the level of
dendrites and dendritic spines in human slices.
Our study marks the first time that dibucaine-mediated pro-
tection of synaptic circuitry was confirmed in the penumbral zone
in vivo. In the photothrombotic model, there is injury to the
endothelium and microvasculature and early (within 15 minutes)
breakdown of the BBB as evidenced by Evans blue leakage in the
ring zone and some in the central penumbra [37]. Texas Red
dextran (70 kDa) also leaks into the brain parenchyma after
photothrombosis as assessed by signal detection outside capillaries
[49,50]. Perhaps the much lighter dibucaine (379.9 MW) can leak
quickly under these conditions, thus providing protection for
neurons and their dendrites. Because we administered dibucaine
after the induction of photothrombosis, we were not able to assess
the ability of dibucaine to delay the onset of the initial spreading
depolarization as in our slice experiments. Instead, the critical
findings of our in vivo experiments involved dibucaine’s effect on
spreading depolarization-induced dendritic beading. Terminal
dendritic beading during ischemia is an early sign of acute injury
leading to neuronal death [15,51,52]. Though the nonirradiated
penumbra-like area at risk inside the lesion undergoes progressive
hypoperfusion [15], penumbral dendrites have the ability to
recover from spreading depolarization-induced beading, but this
recovery is finite and depends on the presence of nearby flowing
capillaries and thus the amount of energy available [15,49,50].
Remarkably, spreading depolarization-induced dendritic beading
was significantly decreased following administration of dibucaine
in intact mice subjected to focal photothrombotic occlusion.
Importantly, terminal dendritic beading was observed only in
one dibucaine-treated animal, suggesting that dibucaine-induced
uncoupling of dendritic beading from the passage of recurrent
spreading depolarizations protects dendrites by delaying terminal
injury. Future studies using a different model where spreading
depolarizations are frequently observed (e.g. middle cerebral
artery occlusion) will be necessary to test whether infarct size is
reduced by dibucaine.
The igniting mechanism of spreading depolarization during
ischemia is of major interest, because drugs targeting spreading
depolarization may protect the penumbra from progressively
damaging depolarization waves [4,21]. Sodium channel opening
largely contributes to the depolarizing event although other
channels are involved [7]. This may underlie the finding that
sodium channel blockers are effective in delaying spreading
depolarization but are not able to stop it once initiated [7,53].
Thus, inhibition of terminal depolarization initiation by dibucaine
likely involves an interaction with a sodium conductance because
of its high binding affinity to the sodium channel [22]. Indeed,
delaying the terminal depolarization onset should not be surprising
for 10 mM dibucaine, because at this concentration dibucaine
blocks enough sodium channels to inhibit action potentials and
synaptic transmission. However, as revealed here and in our
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onset at 1 mM yet still preserves synaptic function. There are other
reports where spreading depolarization was delayed by sodium
channel blockers at concentrations that were too low to affect
action potentials [54–56]. Remarkably, dibucaine (at 1 mM)
displayed higher potency in inhibiting terminal depolarization
onset in rodent slices than any other voltage-gated sodium channel
blockers [22].
The mechanism by which dibucaine prevents dendritic beading
despite the continued occurrence of spreading depolarizations is
unclear. Spreading depolarization is characterized by severe
disturbances of ion concentration gradients, resulting in the
redistribution of ions across the membranes of metabolically
compromised neurons [4,7,16]. Mammalian pyramidal neurons
lack functional aquaporins, thus the molecular pathways by which
they accumulate osmotically obligated water and swell during
spreading depolarizations is uncertain [27]. Spreading depolar-
ization possibly engages activation of a large conductance, such as
pannexin-1 hemichannels [57,58]. This should result in bulk water
influx through the osmotically-tight neuronal compartment [27]
leading to neuronal swelling and dendritic beading. It has been
proposed that an interaction with such large ischemia-induced
conductances would be neuroprotective [21] and may explain
dibucaine’s ability to prevent dendritic beading. Importantly, the
success of experiments with dibucaine confirms that human brain
slices are a suitable model system to identify and study potentially
useful therapeutics targeting spreading depolarization. Further-
more, the protection of dendrites from the damaging effects of
recurring spontaneous depolarizations is a surprising finding which
suggests that a useful anti-stroke drug’s therapeutic action may
extend beyond mere inhibition of the spreading depolarization
and that recording spreading depolarizations alone may not
entirely reveal a drug’s potential therapeutic benefit.
Supporting Information
Video S1 Time series showing changes in LT evoked by 15 min
of 100 mM ouabain exposure in a neocortical slice prepared from
tissue obtained from a 7 y.o. female patient (patient # 7, see
Patient Table S1). Time 0 corresponds to the beginning of ouabain
exposure. A slice superfused with standard ACSF undergoes
propagating terminal depolarization within ,5 min of ouabain
application. The terminal depolarization is imaged as an elevated
LT (blue-yellow pseudocoloring signifying cell swelling).
(MOV)
Video S2 Similar time series to Video S1 of a slice from the same
patient (patient #7) pretreated for 1 h with ACSF containing
1 mM dibucaine. Dibucaine incubation considerably delays the
latency to the propagating terminal depolarization onset (6.8 min)
and decreases peak cell swelling in the slice during co-superfusion
with ACSF containing 100 mM ouabain and 1 mM dibucaine.
(MOV)
Video S3 Similar time series to Videos S1 and S2 of a slice from
the same patient (patient #7) pretreated for 1 h with ACSF
containing 10 mM dibucaine. Dibucaine incubation considerably
delays the latency to the propagating terminal depolarization onset
(9.4 min) and decreases peak cell swelling in the slice during co-
superfusion with ACSF containing 100 mM ouabain and 10 mM
dibucaine.
(MOV)
Table S1 Patients in this study. Notes: FCD, focal cortical
dysplasia [classification from: [59] Palmini A, Najm I, Avanzinin
G et al. Terminology and classification of cortical dysplasias.
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